The year 2025 marks the 85th anniversary of the American Diabetes Association (ADA) Scientific Sessions, yet it arrives ...

Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

The therapy leverages the company’s intravitreal vector, R100, invented using the Therapeutic Vector Evolution platform.

A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address ...

The software-based intervention aims to reduce brain hypersensitivity in patients with migraine by modulating responses to environmental and internal stimuli through a 12-week program.

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people ...

Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a publication in the ...

Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, is entering the second quarter of its financial year with "clear momentum", despite the first quarter being ...

The U.S. digital therapeutics market size was valued at $1.16 billion in 2019 and is expected to reach $5.08 billion by 2027 with a CAGR of 19.2% during the forecast period. Increase in adoption of ...

This all suggests that orforglipron is useful for both treating diabetes and weight loss ... news for investors in Novo Nordisk and Viking Therapeutics, both of which lag Lilly in the race ...

and later acquired a diabetes-focused platform through its purchase of assets from the defunct digital treatment developer Better Therapeutics. “As the first authorization in our neurology ...